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ABSTRACT
Glomerularplantedantigens (histones,DNA,andC1q)arepotential targetsofautoimmunity in lupusnephritis (LN).
However, the characterization of these antigens in human glomeruli in vivo remains inconsistent. We eluted
glomerular autoantibodies recognizing planted antigens from laser-microdissected renal biopsy samples of 20
patientswith LN.Prevalent antibody isotypesweredeﬁned, levelsweredetermined, andglomerular colocalization
was investigated. Renal and circulating antibodieswerematched, and serum levelswere compared in 104patients
with LN, 84 patients with SLE without LN, and 50 patients with rheumatoid arthritis (RA). Autoantibodies against
podocyte antigens (anti–a-enolase/antiannexin AI) were also investigated. IgG2 autoantibodies against DNA,
histones (H2A, H3, and H4), and C1q were detected in 50%, 55%, and 70% of biopsy samples, respectively.
Anti-DNA IgG3 was the unique non-IgG2 anti-DNA deposit, and anti-C1q IgG4 was mainly detected in subepi-
thelial membranous deposits. Anti-H3, anti-DNA, and anti-C1q IgG2 autoantibodies were also prevalent in LN
serum, which also contained IgG3 against the antigen panel and anti-C1q IgG4. Serum and glomerular levels of
autoantibodies were not strictly associated. High serum levels of all autoantibodies detected, including anti–
a-enolase and antiannexin AI, identiﬁed LN versus SLE and RA. Anti-H3 and anti–a-enolase IgG2 levels had the
most remarkable increase in LN serum and represented a discriminating feature of LN in principal component
analysis. The highest levels of these two autoantibodieswere also associatedwith proteinuria.3.5 g/24 hours and
creatinine.1.2 mg/dl. Our ﬁndings suggest that timely autoantibody characterization might allow outcome pre-
diction and targeted therapies for patients with nephritis.
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Lupus nephritis (LN) is the prototype of autoimmune GN. It
is a clinically relevant condition1 that is potentially causative of
renal failure and death. Early identiﬁcation and treatment is
crucial to block autoantibody deposition and reverse the glo-
merular inﬂammation. There is a consensus about an autoan-
tibody genesis of LN2–5 mainly deriving from experimental
models, but the mechanisms leading to the formation of im-
mune deposits and the development of renal lesions are not
clariﬁed.6
Three categories of autoantibodies have been identiﬁed
that constitute the basis for any pathologic and clinical
consideration. The ﬁrst category targets implanted antigens
(DNA, histones, and nucleosomes),7–10 mainly deriving
from breakdown of apopotic cells. The second category of
antibodies binds C1q, which is a component of the com-
plement cascade accumulating in the kidney in LN. The
third category includes several podocyte antigens, mainly
a-enolase and annexin AI, that have been only recently iden-
tiﬁed.11 Other glomerular antigens can be included as
well.11,12
Evidence from the literature suggests that it is the
combination of all antibodies that produces stable renal
lesions in LN and that different subsets have speciﬁc
implications.12–16 Experimental studies support the role of
anti-DNA antibodies in starting the process2,17 and anti-
podocyte antibodies in its maintainance.11 In the case of anti-
bodies versus DNA and/or DNA components (i.e., histones
and nucleosomes),17 the binding is directed to basement
membrane and mesangial matrix and seems propedeutic
to further immune complex deposition.8,9 Antibodies ver-
sus podocyte antigens induce lupus-like renal lesions in
mice, and the same antigens (i.e., a-enolase) are targets of
nephrogenic antibodies puriﬁed from MLR/MLR lupus-
prone mice.11
Human studies are stillweak, because renal tissueﬁndings
are mainly on the basis of histopathology and electron
microscopy. Relevant information is lacking on the com-
position and characteristics of autoantibodies on the basis of
an in vivo characterization of Igs microeluted directly from
renal biopsies; until recently,11 studies addressing compo-
sition and quality of renal autoantibodies in human LNwere
limited to postmortem kidney tissues.18,19 Technologies are
now available that allow minute isolation of glomeruli from
fresh renal biopsies and characterization of autoantibodies/
antigens. Laser microdissection and proteomics already
have been successfully used to widen the spectrum of podo-
cyte antigens in LN11 and other primary autoimmune
GNs.20–23
We applied the same laboratory approach (laser microdis-
section and proteomics) to characterize renal autoantibodies
directed against implanted antigens (i.e., histones H1, H2A,
H2B, H3, and H4, DNA, and C1q) in renal biopsies and serum
of the same 20 patients already used for studying podocyte
antigens.11 Matched tests with serum antibodies (here includ-
ing anti–a-enolase and antiannexin AI IgG2) were done in a
large cohort of patients with LN or SLE at different stages of
the diseases compared with rheumatoid arthritis (RA) and
controls.
RESULTS
Characterization of Glomerular Autoantibodies Versus
Implanted Antigens
For the studyof glomerular expression of autoantibodies, renal
biopsies from 20 patients with LN who underwent the pro-
cedure at the onset of urinary symptoms were used (Table 1).
Serum levels of autoantibodies were determined in the same
cohort.
Anti-DNA and Antihistones
Autoantibodies versus DNA (plasmid DNAwas used as a ﬁxed
antigen) and its protein component histones were detected
with different patterns in glomerular eluates.
As shown in Figure 1A, signiﬁcant amounts of anti-DNA
IgG2 and IgG3 were present with the same intensity in
,50% of the same biopsies (6 of 20 and 8 of 20, respec-
tively). Colocalization of IgG2 and IgG3 with DNA (Figure
1B) was present with the same intensity in all positive
biopsies.
Antihistone H2A, H3, and H4 were primarily of the IgG2
isotype. Other isotypes were negative; anti-H1 and anti-H2B
could not be detected (Figure 1C). Anti-H3 IgG2 was the ma-
jor antihistone component (positive in 10 of 20), although it
presented a weak positivity (Figure 1C); strong reactivity was
found in only one sample. In general and with some variabil-
ity, histone expression within glomeruli was diffuse (most ev-
ident for H4), but colocalization with IgG2 was segmental
(Figure 1D).
Anti-C1q
Anti-C1q autoantibodies were present in several glomerular
elutes (Figure 1E). They principally consisted of IgG2 and
IgG4 that were differently distributed in 20 biopsies: patients
positive for IgG4 (patients 1, 4, 5, and 16) were negative for
IgG2, and vice versa, patients 2, 10, 19, and 20 were positive for
IgG2 and negative for IgG4. Actually, only four biopsies had a
strong/medium positivity for anti-C1q IgG2; positivity to
IgG4 was medium strong in four patients with class V LN
and low medium in two patients with class IV. One strongly
positive patient had an undetermined pattern (Tables 1 and 2).
To exclude a phenomenon of aggregation between IgG4 and
IgG2,24 the same dot blot was repeated along a gradient of
NaCl (0.15–1.5 M) to disrupt potential aggregates between
the two Igs: results excluded this interaction (Supplemental
Figure 1). Colocalization of C1q with IgG2 and IgG4 is
shown in Figure 1F. In the case of IgG2, colocalization was
not widespread, and there were areas where the two compo-
nents were well separated (Figure 1F, class IV). Colocalization
of IgG4 was negative in all patients of pure proliferative lesions
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(including patient 13), whereas it was positive in a patient with
subepithelial immune deposits (class V).
Multiple Glomerular Autoantibody Expressions and Correla-
tion with Serum Antibodies
Table 2 shows the glomerular level of each antibody; in Fig-
ure 1G, multiple positivities were analyzed with cluster anal-
ysis (heat map). The results conﬁrmed predominance
of IgG2 versus endogenous glomerular antigens (anti–
a-enolase and antiannexin AI) followed by anti-DNA and
anti-C1q IgG2. In some cases, IgG2 and IgG3 were of the
same intensity, which was the case of anti-DNA. Class spec-
iﬁcity was only found for anti-C1q IgG4, which was mainly
detected in class V LN and colocalized in subepithelial de-
posits (Figure 1F).
Glomerular and serum levels of speciﬁc antibodies in the
same 20 biopsies were determined and tentatively correlated
(Supplemental Figure 2). The major ﬁnding was that, overall,
glomerular deposition was independent from serum levels.
Glomerular levels of a few antibodies that were low in serum
(i.e., anti-C1q IgG2-IgG3 and anti-DNA IgG2-IgG3; level in
serum=0.5 mg/L or less), were, in some patients, comparable
with anti–a-enolase IgG2 (serum level=50–100 mg). The ra-
tio between glomerular and serum concentrations was con-
sequently higher by a variable factor from 40 to 250 for the
former group of antibodies compared with anti–a-enolase
IgG2 (median=1.1, 2.5, 0.4, and 1.6 versus 0.01), implying
that afﬁnity of each antibody to its target is quite variable.
Using Spearman analysis, only a few correlations among se-
rum and glomerular levels of antibodies of secondary impor-
tance (i.e., anti–H4-IgG1 and IgG2 and anti-H3 IgG2) were
observed (correlogram in Supplemental Figure 2). When pa-
tients were subdivided according to the level of antibody in
glomeruli (i.e., high and low antibody), no important differ-
ence could be seen in serum levels, with the exception of anti-
H2A and anti-H3 IgG2 (Figure 1H). However, antihistone
antibodies are minor glomerular components, and correla-
tions with serum levels seem of no deﬁnite value.
Serum Autoantibodies Versus Implanted Antigens
Serum antibody levels were determined in 334 patients
belonging to different SLE categories with (n=104) and
without (n=84) LN, 50 patients with RA, and 96 normal
controls. Dot blot was used for characterizing isotypes,
and speciﬁc ELISAs were devised for determining serum
levels.
Anti-H2A, -H3, and -H4
The isotypes of antihistone antibodies in serum included
IgG1, IgG2, and IgG3, with a prevalence of IgG2 (Figure 2, A
and B). Serum levels of anti-H3 IgG2 and IgG3 were higher in
LN compared with the other groups (P,0.001); 58% and
47% of patients with LN had serum levels of IgG2 and
IgG3, respectively, higher than the 95° percentile of normality
Table 1. Pathology characteristics and positivity/amount of different autoantibodies in glomerular eluates in 20 patients
with LN
Patient Sex
Age
(yr)
Biopsy Class
Renal Antigen Ab Implanted Antigen Ab
a-Enolase
IgG2
Annexin
AI IgG2
H2A IgG2 H3 IgG2 H4 IgG2 DNAIgG2 DNA IgG3 C1q IgG2 C1q IgG4
1 Man 16 2010 V ++ + + ++++
2 Man 22 2005 III +++ + + +++
3 Man 19 2010 V +++
4 Woman 18 2009 nd ++++ + + ++ ++ ++++
5 Woman 25 2005 V ++++ +++ +++ ++ ++++
6 Woman 28 2005 nd ++++ +++ + + +
7 Woman 20 2007 II ++++ ++ ++ + + +
8 Woman 17 2009 IV + V ++ + +
9 Woman 25 2004 V + + + ++ + ++
10 Woman 43 2010 IV ++++
11 Woman 44 2010 IV + V + ++
12 Woman 53 2010 III + ++ ++ +
13 Woman 34 2009 IV + ++ + ++
14 Woman 40 2009 III ++ ++ ++
15 Woman 25 2009 V +++ + +++ +++
16 Woman 38 2009 V +++ ++++ + +++ + ++++ ++++ +++
17 Woman 50 2009 IV +++ +++ ++ + + +
18 Woman 35 2010 IV +++ +++ + +
19 Woman 31 2011 IV +++ ++ + +++
20 Woman 27 2011 IV +++
These patients underwent a renal biopsy at the time of the enrolment and had their renal tissue processed with laser capture for antibody characterization. Data
relative to the antirenal antigen antibodies have been presented in a separate paper11 and are here shown for comparison with antibodies versus implanted
antigens that are the topic of this study. Results are given as nanograms per 100 ml eluate and also expressed as semiquantitative values. nd, Not determined.
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Figure 1. Glomerular autoantibodies and implanted antigens: isotypes in single biopsies. Renal biopsies obtained from 20 patients with
LN (Supplemental Table 1) at the time of appearance of urinary symptoms were processed with laser capture, and microdissected
glomeruli were used for elution of autoantibodies. (A, C, and E) Deﬁnition of most representative isotypes on pooled samples was done
with dot blot analysis and followed by single-biopsy analysis. The same glomerular eluates used for anti–a-enolase and antiannexin AI
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(Figure 2D, Table 3); ROC analysis showed a medium degree of
speciﬁcity/sensitivity for both antibodies, particularly for LN ver-
sus SLE (areas under the curve=0.75 and 0.64, respectively).
Anti-DNA
Anti-DNA isotypes in serum included IgG2, IgG3, and aminor
component of IgG4 (Figure 2A). Serum levels of anti-DNA
IgG2 and IgG3 were higher in LN compared with SLE
and other groups (P,0.001) (Figure 2E, Table 3). ROC
curves showed a very high speciﬁcity of both antibodies
in differentiating LN and SLE (area under the curve=0.83
for both), whereas the performance was lower in the case
of comparison with AR (area under the curve=0.62 for
both).
antibodieswereprocessed fordeﬁnitionof isotypesof antibodies versus implantedantigens (DNA,H2A,H3,H4, andC1q). In all cases, after
the deﬁnition of prevalent isotype, competition experiments using the same glomerular eluates and increasing amounts of the speciﬁc
antigen from 5 to 15 ng to saturate antibodies were done (not shown). In B, D, and F, the colocalization of each implanted antigen with the
most relevant antibodies in single renal biopsy samples (IgG2 and IgG3 for DNA; IgG2 for H2A, H3, and H4; and IgG2 and IgG4 for C1q) is
reported. In B and D, double IF staining was evaluated for each antigen (red) and IgG2 (green), whereas in F, the antigen is in green and IgG is
in red. Merged images are reported in yellow. The last box in Figure 1 D is the magniﬁcation of white frame. For anti-C1q IgG4, confocal
images include different renal biopsy specimens with LN classes III–IV and V. Colocalization was absent in the case of class IV LN, whereas it
was well evident in subepithelia deposits in biopsies of patients with class V LN.Magniﬁcation of the same ﬁgures is in Supplemental Figure
3. Scale bar, 20mm in A–C; 10 mm.Original magniﬁcation,3630. In G, the hierarchical cluster analysis heat map for single antibody in each
renal biopsy is shown: antibody intensities (colors from black [high] to gray [medium] to white [low]) are reported in lines and refer to single
patient biopsies that are reported at the bottom of the ﬁgure. Results are given for 20 patients with LN of our study cohort and four normal
kidneys; a semiquantitative evaluation of the same data is reported in Tables 1 and 2. A preliminary heat map analysis of autoantibody
expressed in biopsies of 20 patients enrolled in the study has been already presented in the ﬁrst part of this study11; this ﬁgure includes anti-
DNA IgG3 and anti-C1q IgG4, which have been only now characterized. In H, the serum levels of antibodies are reported considering two
different population of patients with detectable (high) and undetectable (low) glomerular levels. The numbers of positive/negative con-
sidering the overall numbers of 20 biopsies are shown. Glomerular levels of each antibody were calculated from the dot blot and the
standard curve that includeddifferent concentrations of each antibody (Supplemental Figure 4). For serum levels, speciﬁc ELISAswere used
as described in Concise Methods.
Figure 1. Continued.
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Anti-C1q
Anti-C1q antibodies in serum included IgG2
and IgG4 isotypes. Serum levels were higher
in LN than in other groups for both
(P,0.001); 57% and 68% presented serum
levels of IgG2 and IgG4, respectively, higher
than the 95° of normality (Figure 2F, Table
3). Speciﬁcity was high in particular for LN
versus controls (areas under the curve=0.88
and 0.93, respectively).
Clinical Correlations
High serum levels of all antibodies (in-
cluding anti–a-enolase and antiannexin
AI IgG2) allowed us to identify patients
with LN: antipodocyte differentiated LN
from AR, whereas anti-H3 and anti-DNA
had better performance in differentiating
LN from SLE (Figure 3A). Principal com-
ponent analysis (PCA) was used as the
multivariate discriminating test. When
patients were analyzed separately in re-
spect to autoantibody levels (here includ-
ing antipodocyte antibodies), LN, SLE,
RA, and controls were well discriminated
(Figure 3B); anti–a-enolase IgG2 and
anti-H3 IgG2/IgG3 contributed signiﬁ-
cantly in characterizing different popula-
tions (Figure 3C). Actually, anti–a-enolase
IgG2 and anti-H3 IgG2 serum levels pre-
sented the highest median fold increment
(10-fold for both) (Figure 3D), implying
that there are patients with very high, me-
dium, and normal levels. High levels of
both anti-H3 IgG2 and anti–a-enolase
IgG2 were associated with heavy protein-
uria (.3.5 g/24 h) and reduced renal func-
tion (creatinine.1.2% mg); intermediate
serum levels were associated with inter-
mediate proteinuria (1–3.5 g/24 h),
whereas low levels had no association.
Serum levels of other antibodies presented
less impressive increment but were overall
still associated with proteinuria (Figure 4,
C–J).
DISCUSSION
This studywas designed to identify and char-
acterize autoantibodies versus implanted
antigens in biopsies of patients with LN
in vivo. This is the second part of a study on
lupus renal antigens in human LN, and
ﬁndings related to the identiﬁcation of
Figure 1. Continued.
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podocyte antigens have been recently published in JASN.11 In
this second approach, antibodies versus anti-implanted anti-
gens were eluted from laser-microdissected glomeruli of the
same 20 biopsies and characterized in respect to composition,
isotype, amount, and colocalization in each biopsy; the merge
between glomerular and serum levels was a crucial part of the
study.
Correlation with pathology and clinical characteristics
with patients with LN led to relevant conclusions on the basis
of the following major results: (1) autoantibodies versus po-
docyte antigens predominate in renal biopsies over implanted
antigens, which were still present; (2) IgG2 represented the
most relevant isotype in all cases followed by anti-DNA IgG3;
anti-C1q IgG4 was limited to membranous deposits (class V);
(3) anti-C1q IgG4/IgG2 and anti-DNA IgG2/IgG3 deposition
occurred despite low serum levels, suggesting high afﬁnity;
and (4) IgG2 also predominated in serum, but the isotype
panel was less stringent; in some cases (i.e., anti–a-enolase
and anti-H3), IgG2 increment was higher than 10-fold of
normal levels and identiﬁed a category of patients with high
risk of developing proteinuria and renal failure. Altogether
and with some differences, high serum levels of IgG2/IgG3
antibodies identiﬁed with very high speciﬁcity LN versus
SLE/RA: anti–a-enolase and antiannexin AI IgG2 better dif-
ferentiated LN from AR (89% speciﬁcity), and anti-H3 and
anti-DNA had a better performance in differentiating LN
from SLE (75% and 83% speciﬁcity, respectively).
Owing to the novelty of the approach used here (laser
microdissection and proteomics) and considering that these
are the ﬁrst data on renal autoantibodies in human LN in vivo,
ﬁndings should represent the starting point to reconsider
mechanisms of LN and develop biomarkers. The ﬁrst issue
is pathogenesis, which is mainly focused on target antigens
and antibody isotypes. With respect to
target antigens, our ﬁndings conﬁrm pre-
vious observations: DNA/histones as tar-
gets of autoimmunity in human LN have
been from time to time shown by immu-
noelectronmicroscopy9; the implication
of a-enolase and annexin AI has been
shown in the companion paper11 and is
further discussed here. Actually, other stud-
ies reported an association of antiannexin
antibodies with peculiar autoimmune con-
ditions, such as discoid lupus25 and anti-
phospholipid syndrome, typically a serious
condition potentially causing vascular
events.26–28 Therefore, our results go in
the direction of other reports that already
suggested a generic implication of anti-
histones, anti-DNA, and antipodocyte
antibodies.11,29,30
Looking at the renal composition of
autoantibodies, a relevant ﬁnding here is
the preponderance in glomeruli of anti-
bodies of the IgG2 isotype (anti–a-enolase/annexin AI andH3
histone) with little amounts of anti-DNA IgG3 and predom-
inant colocalization of anti-IgG4 with C1q in subepithelial
deposits of class V biopsies. IgG2 were unexpected, because
these antibodies are weak complement activators compared
with IgG1 and IgG3.31 Immunoﬂuorescence on the same bi-
opsies used for the proteomic approach conﬁrmed IgG2 prev-
alence but also showed IgG1 and IgG3 (Supplemental Figure 3).
We cannot exclude that IgG1 and IgG3 are directed versus
other glomerular autoantigens, and research should now focus
on this point, because there are at least 11 podocyte antigens
that are good candidates for being investigated.11 We also con-
sidered that the timing of the biopsy probably has strong in-
ﬂuence on this aspect; anticipating the biopsy at the time of
presentation of minimal urinary signs would allow the iden-
tiﬁcation of more precocious antibodies, because it is
known32–34 that renal immune deposits may anticipate the
onset of clinical symptoms.
Presence and colocalization of IgG4 with C1q in subepi-
thelial membranous deposits are also new and of interest,
clearly suggesting that membranous and proliferative lesions
originate from partially different mechanisms. The ﬁnding
about IgG4 prevalence in subepithelial deposits creates a link
with idiopathic membranous nephritis (MGN) that typically
is characterized by IgG4 deposition.20,21,35,36 The basic con-
cept that primary (as in the case of MGN) and secondary
subepithelial deposits (as in the case of class V LN) can be
differentiated on the basis of the IgG isotype should, there-
fore, be reviewed considering the presence of anti-C1q IgG4
in the latter case. In both conditions, there is a promiscuity of
target antigens (anti-PLA2R, anti-AR, and anti-SOD in
MGN20,36 antipodocyte and anti-implanted in LN) and anti-
body isotypes that should bring us to consider a more
Figure 1. Continued.
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complex pathogenesis than expected. A clearly speculative
possibility is that, in both MGN and LN, some antigens/anti-
bodies come ﬁrst (e.g., anti-PLA2R inMGN and anti-implanted
in LN) and are followed by others that represent a general
podocyte response to the former autoimmunity. Anti-C1q
IgG4 clearly represents a second-phase antibody, because
C1q deposits develop after an initial autoimmune process
has started. This ﬁnding supports the two-phase theory
above.
Concomitance of IgG2 prevalence in renal glomeruli and
serum antibodies conﬁrms and further supports the idea of the
key importance of antibodies of IgG2 isotype in human lupus
GN. It is of note that, in the case of anti–a-enolase IgG2, serum
levels are in the range of hundreds of milligrams per liter, with a
Table 2. Levels of each antibody in glomerular eluates and serum were determined in 20 patients with LN for whom a renal
biopsy was available
Patient
a-Enolasee Annexin
AI
H2A H3 H4 DNA C1Q
IgG1 IgG2 IgG3 IgG2 IgG1 IgG2 IgG3 IgG1 IgG2 IgG3 IgG1 IgG2 IgG3 IgG2 IgG3 IgG2 IgG4
Ab eluted from
glomeruli (ng)
1 0.2552 0.0761 0.1872 1.4884
2 0.9197 0.1095 0.0750 0.6669
3 0.5621
4 2.0012 0.1102 0.0741 0.2493 0.2547 1.6138
5 1.3697 0.5005 0.8613 0.2465 1.4047
6 2.0533 0.4996 0.0756 0.0761 0.0940
7 1.2890 0.2585 0.2095 0.1143 0.1187 0.1543
8 0.2614 0.0525 0.1745
9 0.0751 0.0467 0.1279 0.2859 0.1850 0.2600
10 1.8999
11 0.0589 0.2306 0.0740
12 0.1097 0.3023 0.2520 0.0643
13 0.0771 0.2273 0.0538 0.2789
14 0.2617 0.2547 0.2689
15 0.8172 0.0769 0.9267 0.9266
16 0.4111 1.9356 0.0753 0.9899 0.0679 2.0702 2.0078 0.2510
17 0.5294 1.5220 0.2098 0.0552 0.1205 0.1052
18 0.5287 1.4708 0.0842 0.0924
19 0.5307 0.2150 0.0395 0.7639
20 0.6510
Serum Ab (mg/L)
1 0.56 41.08 2.19 2.88 0.01 0.21 0.16 0.00 0.54 0.01 0.02 0.13 0.01 0.14 0.60 0.06 0.25
2 0.90 90.00 3.84 4.41 0.21 0.62 0.24 0.02 0.73 0.08 0.01 0.15 0.01 0.18 0.58 0.07 0.25
3 0.58 73.40 1.97 2.37 0.01 0.03 0.01 0.00 0.14 0.01 0.02 0.10 0.01 0.12 0.40 0.06 0.23
4 1.58 103.83 4.00 3.98 0.02 0.02 0.02 0.00 0.15 0.01 0.01 0.14 0.01 0.16 0.64 0.04 0.25
5 0.32 25.33 2.28 6.03 0.01 0.02 0.01 0.00 0.14 0.01 0.02 0.06 0.01 0.13 0.60 0.06 0.26
6 1.90 104.48 4.14 3.39 0.01 0.02 0.05 0.00 0.39 0.12 0.07 0.24 0.01 0.11 0.27 0.06 0.27
7 0.47 61.80 2.08 3.89 0.02 0.34 0.13 0.03 0.18 0.11 0.03 0.59 0.01 0.18 0.64 0.08 0.27
8 0.56 10.39 2.28 5.80 0.01 0.03 0.01 0.01 0.63 0.01 0.02 0.42 0.01 0.09 0.24 0.07 0.28
9 0.50 14.59 0.97 4.01 0.41 0.93 0.33 0.01 0.60 0.10 0.02 0.31 0.02 0.17 0.63 0.08 0.29
10 0.66 87.33 2.19 5.64 0.01 0.03 0.01 0.00 0.13 0.01 0.02 0.03 0.01 0.08 0.36 0.07 0.22
11 0.24 13.28 2.17 2.16 0.01 0.03 0.01 0.00 0.12 0.01 0.01 0.13 0.01 0.17 0.55 0.03 0.20
12 0.46 10.36 1.70 2.81 0.01 0.02 0.01 0.00 0.12 0.01 0.01 0.04 0.01 0.18 0.52 0.07 0.27
13 0.29 41.80 2.39 2.25 0.01 0.03 0.01 0.00 0.17 0.01 0.09 0.40 0.01 0.14 0.60 0.07 0.25
14 0.41 72.93 2.36 3.68 0.01 0.02 0.01 0.00 0.11 0.01 0.01 0.10 0.01 0.14 0.61 0.08 0.26
15 0.48 84.78 1.67 4.80 0.01 0.22 0.05 0.00 0.28 0.01 0.01 0.15 0.01 0.17 0.55 0.04 0.16
16 0.58 88.72 1.14 4.58 0.51 0.82 0.32 0.03 0.84 0.15 0.06 0.18 0.02 0.17 0.56 0.07 0.24
17 0.47 80.95 2.40 3.61 0.02 0.23 0.12 0.03 0.29 0.09 0.02 0.03 0.01 0.18 0.55 0.01 0.19
18 0.57 48.77 1.02 5.19 0.01 0.02 0.01 0.00 0.11 0.01 0.02 0.02 0.01 0.17 0.59 0.07 0.28
19 0.52 45.77 0.80 6.03 0.01 0.03 0.01 0.00 0.42 0.14 0.02 0.03 0.01 0.17 0.56 0.02 0.19
20 0.27 35.24 0.96 2.66 0.01 0.02 0.01 0.00 0.04 0.01 0.02 0.04 0.01 0.14 0.64 0.07 0.28
For serum antibody levels, speciﬁc ELISAs were used. For their concentration in glomerular eluates, a dot blot was used (Concise Methods). In some cases, levels
were below the limit of detection and not reported. Results are given in nanograms per 100 ml eluate.
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fold increment up to 10 times over the 95° of normality, which is
the level rarely reported in human pathology. However, animal
models already highlighted the role of anti-DNA IgG2 in deter-
mining immunodeposits inmice: almost allmodels of LN induced
by anti-DNA clones used mAbs of the IgG2 isotype.11,17,37
Characterizing renal and circulating antibodies allowed us to
address several questionsabout the signiﬁcanceofbiomarkers. In
the case of LNand despite recent evolution,38,39 no biomarker of
glomerular pathology is so far available for patients with SLE,
and urine analysis still represents the unique index of renal in-
volvement. Inﬂammatory molecules expressed by renal tubular
epithelia, such as CSF-1, are of clear interest, but their rise may
underscoreminimal proteinuria and be a part of a generalmech-
anism of tubular cells activation.40–42
Proteinuria is very discriminative between LN and disease
controls (SLE, RA, and normal controls) but represents the
outcome and cannot be used in positive prediction, for
deﬁnition, in LN. Therefore, any predictive efforts should be
targeted to immunologic biomarkers of lupus activity as we
here propose. Whether the autoantibodies proposed in our
study anticipate proteinuria remains to be proven by pro-
spective studies, which are now in progress.
On the road of biomarker development, despite that we
suggest that a complex multisystem is involved, we also
propose a simpliﬁcation that may evolve
from bench to bedside. Reﬁning target
molecules (no H1/H2B/H4 detected), de-
fying isotype (main focus on IgG2) and
new antigens (a-enolase and annexin AI),
and introducing a quantitative assay
would improve the predictive and statisti-
cal signiﬁcance. Antipodocyte and anti-
DNA/H3 antibodies might represent the
bulk of an assay for monitoring patients
and trying to anticipate renal lesions. Ow-
ing to the prevalence of IgG2 and the ex-
istence of a strong correlation between
IgG2 and IgG3, to determine only IgG2
would simplify the role of clinical chemists.
Overall, a chip targeting serum anti–a-eno-
lase, antiannexin AI, anti-H3, and anti-DNA
IgG2 antibodies would be of easy assembly
and limited cost. Anti-C1q should also in-
clude IgG4. The real issue now is to under-
stand how the above antibodies can predict
the evolution to LN/renal failure, which
means deﬁning the temporary limits inwhich
they precede the onset of proteinuria. New
prospective studies in patients with uncom-
plicated SLE are now in progress to address
this crucial point and deﬁne the panel of au-
toantibody of interest.
Finally, in clear contrast with previous
papers, we could not conﬁrm other anti-
bodies as biomarkers of LN (e.g., anti–
a-actinin, antilaminin, antiﬁbronectin, antimyosin, and
anticollagen).5,43 In all cases, the target antigen is represented
by ubiquitous proteins well expressed in both podocytes (the
cell model here used) andmesangial cells. Actually, we did not
show the presence of such antibodies in glomeruli, and we
believe that they do not represent a major quota of autoanti-
bodies in serum. Crossreactivity with anti-DNAcould explain
the difference with our results44–46
In conclusion, several new hints on LNderive from the direct
analysis of antibodies directly eluted from glomeruli of patients
with LN. Speciﬁc IgG2 deposition in most cases and prevalent
IgG4 in membranous deposits suggest different mechanisms or
phases in renal lesions. Analysis of circulating antibodies
underscored a main position of IgG2 targeted to the same renal
antigens and proposed a panel of antibodies that could represent
the start point for a predictive assay to be used in prospective
studies.
CONCISE METHODS
Patients
Overall, 184 patientswith SLEwere included in the study (Supplemental
Table 2), and their sera were used for studies on circulating
Figure 2. Circulating autoantibodies and implanted antigens in serum of patients with
LN. (A) For each antibody detected in serum (including all implanted antigens), the
deﬁnition of isotype was done with dot blot analysis. (B) Determination of antibody
levels in serum was done with self-made ELISAs in 184 patients with SLE, 104 of whom
had LN. Results are expressed as medians and interquartile ranges. (C–G) Comparison
of serum levels for each antibody (including ROC curves) in SLE, LN, and AR. The same
data are reported in Table 3. ROC curves for antibodies with high circulating levels
were calculated to determine speciﬁcity and sensitivity versus SLE, RA, and normal
subjects. *P,0.05; **P,0.01; ***P,0.001.
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autoantibodies; 104 patients with LN were recruited when
they underwent a renal biopsy for diagnostic purposes, and all
had a diagnosis of LN on the basis of typical renal lesions. Fresh
frozen renal samples were available for 20 patients and used for
the proteomic approach (Supplemental Table 1). For histol-
ogic evaluation of kidney disease, Dubosq–Bresil solution-ﬁxed
tissues were embedded in parafﬁn, sectioned, and stained with
hematoxylin/eosin, Masson’s trichrome, periodic acid–Schiff,
and silver methenamine periodic acid–Schiff. Routine IMF studies
on frozen sections were performed using anti-human IgG, IgA,
IgM, C1q, C3, and ﬁbrinogen antibody. Sera were also obtained
from 100 normal controls of the same age. Routine serological
analyses were done with commercial assays (Supplemental Mate-
rial).
Normal Kidneys
Noncarcinomatousportions of kidneys removed for renal cancerwere
obtained from four patients and processed as negative tissue controls
with laser capture.
Ethical Committee
Permission for the study was given on June 10, 2010, by the Ethical
Committee of San Carlo Borromeo Hospital. Informed consent for
the study was obtained from all participants.
Figure 2. Continued.
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Cell Culture
Human conditionally immortalized podocyte cell lines47 were a gift
from M.A. Saleem (University of Bristol, Bristol, UK). They were
cultured in RPMI 1640 supplemented with 10% inactivated
FCS, insulin transferrin selenium, 100 units/ml penicillin, and
100 mg/ml streptomycin.
Antibodies
Antibody sources are reported as Supplemental Material.
Laser Capture Microdissection and Elution of Antibodies
from Renal Biopsy Tissue
Laser capture microdissection and elution of antibodies were
done as already described21,23; details are given in Supplemental
Material.
Two-Dimensional Electrophoresis
Two-dimensional electrophoresis of podocyte extracts (gift from
M.A. Saleem) was performed in soft gels as described.48 A detailed
description is given in Supplemental Material.
Monodimensional Electrophoresis
Gradient PAGE was done according to Laemmli.49
Western Blot
Western blotwith glomerular eluates and serawas donewith podocyte
cell line whole extracts separated by either mono- or bidimensional
electrophoresis. Equipment and technique of analysis are described in
Supplemental Material.
Gel/Membrane Staining and Image Analyses
After separation in SDS-PAGE gels, proteins were visualized by a double-
stainingprocedure: themethyl-trichloroacetatenegativestainingfollowed
by theblue silvercolloidalCoomassie50 forpreparativemass spectrometry
analysis. Images of stained gels were digitized using a GS800 photometer,
andWestern blots were acquired using aVersaDOC400. All images were
analyzed with the PD Quest software (Bio-Rad, Hercules, CA).
Classic Immunoﬂuorescence and Colocalization
Renal biopsy specimens were embedded in OCT (Tissue Tek; Miles
Inc., Elkhart, IN) and stored in liquid nitrogen; 3-mm sections were
Figure 2. Continued.
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cut by a cryostat (Leica CM1850; Leica Mycrosystems) and placed on
poly–L-lysine–coated glass slides for indirect immunostaining. De-
tails of staining are given in Supplemental Material.
Characterization of Autoantibody Isotype and Levels in
Single-Biopsy Eluate
Autoantibody isotypes for both endogenous and implanted antigens
and single-biopsy levels were evaluated with dot blot using a Bio-Dot
apparatus (Bio-Rad): the nitrocellulose membrane was prewetted in
TBS and mounted on the apparatus. Constant amounts of recombi-
nant protein (100 ng) in TBS were placed on the nitrocellulose
membrane for 4 hours at room temperature and then, at 4°C
overnight; a vacuum was then applied for a few minutes. The nitro-
cellulose was then gently removed and saturated with 5%BSA in TBS.
Samples (glomerular eluates and sera) diluted 1:50 in TBS-T (0.05%
[vol/vol]) and 1% (wt/vol) BSA were placed on the membrane and
left for 6 hours at room temperature and then, at 4°C overnight; at the
end, the membrane was washed three times in TBS-T. Incubation
with HPR–anti-human IgGs (IgG1, IgG2, IgG3, and IgG4 diluted in
1% [wt/vol] BSA in TBS-T) was performed for 4 hours at room
Figure 3. Clinical characteristics within different patients with LN on the basis of serum antibody levels. For this comparison, data already
shown in Figures 1 and 2 and Tables 1 and 2 were analyzed with hierarchical cluster analysis and PCA. (A) The former test combines and
compares simultaneously serum levels of each speciﬁc antibody (and includes different isotypes); the resulting heat map, where colors from
red (maximum) to green (minimum) indicate the relative abundances, gives an estimate of how different parameters separate patients on
the basis of the presence of nephritis. It seems that serum anti–a-enolase and antiannexin AI IgG2 separate LN and AR better than other
antibodies, whereas anti-H3 IgG2/IgG3 and anti-DNA do it for LN versus SLE. (B) PCA gives an overall picture of statistical power of every
single clinical and laboratory parameter. When all patients were analyzed with respect to autoantibody levels (here including antipodocyte
antibodies), the four population of LN, SLE, AR, and normal controls were clearly separated (different colors). When proteinuria was in-
cluded in the analysis, the same result was obtained according to which of the four population was comparably separated. (C) Considering
LN alone, anti–a-enolase IgG2 and anti-H3 IgG2/IgG3 contributed signiﬁcantly in characterizing these patients, whereas proteinuria and
other clinical tests (VES, CPR, renal function, etc.) were of no value. (D) Serum antibodies presented in some case a notable fold increment
that reached 10 times the 95° of normality. Anti-H3IgG2 and anti–a-enolase IgG2 had the highest performances.
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Figure 4. Clinical associations of each antibody with relevant clinical characteristics. Odd ratios and conﬁdence intervals were calculated
for the association of each antibody with relevant clinical characteristics, such as proteinuria, renal function, and lupus ﬂare (A-J). Anti–-
enolase IgG2 and anti-H3 IgG3 had the best performance in relation to renal parameters (proteinuria and renal function), and anti-C1q
and anti-DNA better correlated with lupus ﬂares.
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temperature. The membrane was then washed three times for 15
minutes each with TBS-T before developing the immune reaction
with SuperSignal West Pico Chemiluminescent substrate (Thermo
Fisher Scientiﬁc). A standard curve for each antibody consisted of
different concentrations of HPR-conjugate IgG of different isotypes
(IgG1, IgG2, IgG3, and IgG4), and it was built to cover the whole
range of Ig concentrations in eluates (Supplemental Figure 4). Results
were given as nanograms per 100 ml eluate. Images of stained gels
were digitized using a GS800 photometer, and Western blots were
acquired using a Versa DOC 400. All images were analyzed with the
PD Quest software (Bio-Rad).
ELISA for Determination of Serum Antibody Levels
The following conditions were used for determining serum levels of
each antibody with self-made ELISA; speciﬁc changes, such as the
amount of antigen used, are reported below.One hundredmicroliters
antigenwas used for all; the sameMaxiPrep 96-well plate was used for
every assay. Aliquots (200 ml) of blocking solution (PBS, 5% [wt/vol]
BSA, and 0.05% [vol/vol] Tween20) were put in each well. Serum
samples (100 ml) were diluted 1:50 in PBS-Tween20 (PBST; 0.05%
[vol/vol]), and BSA (1% [wt/vol]) was added and incubated for 4
hours at room temperature and then, at 4°C overnight. After three
washes in PBST, HRP-conjugated anti-human IgGs (IgG1, IgG2,
IgG3, and IgG4) diluted 1:3000 in PBST and 1% (wt/vol) BSA were
incubated at room temperature for 4 hours, and after three washes in
PBST, 100 ml substrate TMB/H2O2 (10:1) was added and incubated
up to 30 minutes. The reaction was stopped by adding 100 ml 0.45 M
H2SO4 to any wells before reading absorbance at 450 nm. A standard
curve was prepared using each HRP-IgG at different dilutions.
Amount of Antigen Related to Different Assay
Recombinant a-enolase (100 ng), annexin AI (5 ng), H2A, H3, and
H4 (45 ng), DNA (40 ng), and C1q (100 ng) were used.
Statistical Analyses
We summarized serum levels of antibodies as medians and inter-
quartile ranges. We used nonparametric Wilcoxon tests for unpaired
data to compare antibody titers in different patient cohorts. We used
two-tailed P values,0.05 as the level of signiﬁcance in all analyses.We
used data on antibodies levels for each patient to build multivariate
data matrix. In PCA, we used orthogonal transformation to convert
the set of possibly correlated observations for each patient into a set of
values of linearly uncorrelated variables (principal components). In
the LN cohort, we used PCA to explain which parameters best de-
scribed the differences versus other patient cohorts. In both cases,
principal components 1 and 2 were used to perform the PCA plot.
Theheatmapof thehierarchical cluster analysis ranked statistically
signiﬁcant differences of antibodies in serum of the whole patient
population and/or glomeruli eluted from 20 biopsies of patients with
LN. Correlations between glomerular and serum levels were analyzed
with Spearman coefﬁcient; for graphical representation, we used a
correlogram with a tree dendrogram, in which similar variables are
coupled according to the results of cluster analysis.
We used univariate andmultivariate logistic regression analyses to
identify risk factors associated with antibodies titer above 95°
percentile. For those antibodies with the great variability (anti–
a-enolase and anti-H3IgG2), we tested the association of same risk
factors with values between 95% and the median, the median and the
third quartile, and above the third quartile. We used linear regression
to test whether serum antibody levels predicted log2 transformation
of proteinuria, serum creatinine, CPR, C3, or C4; the R software was
used for all analyses.
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